{"id":24219,"date":"2024-05-06T21:04:24","date_gmt":"2024-05-06T19:04:24","guid":{"rendered":"https:\/\/ggba.swiss\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/"},"modified":"2024-05-06T21:08:33","modified_gmt":"2024-05-06T19:08:33","slug":"nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/","title":{"rendered":"Nanobacterie obtient un investissement strat\u00e9gique d&rsquo;EP Equity"},"content":{"rendered":"\n<p>Fond\u00e9e en 2008 par le Dr Edouard Alphand\u00e9ry, expert en hyperthermie oncologique, <a href=\"http:\/\/www.nanobacterie.fr\/\">Nanobacterie<\/a> est sp\u00e9cialis\u00e9e dans les traitements non invasifs du cancer utilisant des nanoparticules magn\u00e9tiques synth\u00e9tis\u00e9es par des bact\u00e9ries magn\u00e9totactiques. La soci\u00e9t\u00e9 a \u00e9t\u00e9 \u00e0 l&rsquo;avant-garde du d\u00e9veloppement d&rsquo;une nouvelle m\u00e9thode de traitement et d&rsquo;un nouveau dispositif m\u00e9dical, qui sont maintenant pr\u00eats pour les essais cliniques et les approbations r\u00e9glementaires.<\/p>\n\n\n\n<p>L&rsquo;investissement strat\u00e9gique d&rsquo;EPEI est une \u00e9tape cruciale pour Nanobacterie, car il lui apporte un soutien essentiel dans la phase suivante des essais cliniques pour son traitement du cancer de la prostate. \u00ab L&rsquo;investissement d&rsquo;EPEI est essentiel pour nous \u00e0 ce stade crucial de notre d\u00e9veloppement. Leur confiance dans notre mission et notre technologie nous permet d&rsquo;aller de l&rsquo;avant avec les essais cliniques essentiels pour apporter notre traitement aux patients\u00a0\u00bb, a d\u00e9clar\u00e9 Edouard Alphand\u00e9ry, CEO de Nanobacterie. \u00ab Ensemble, nous \u00e9tablissons un nouveau standard dans le traitement du cancer \u00bb.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Western Switzerland for Precision Oncology Companies (AlphaOnco Swiss)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/tjQbZa9mw9g?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Ce partenariat intervient \u00e0 un moment o\u00f9 Nanobacterie se pr\u00e9pare \u00e0 poursuivre ses recherches et \u00e0 mettre sur le march\u00e9 sa m\u00e9thode de traitement r\u00e9volutionnaire. Le soutien d&rsquo;EPEI permettra \u00e0 Nanobacterie de poursuivre ses travaux innovants dans ce domaine et d&rsquo;\u00e9tendre \u00e9ventuellement sa technologie \u00e0 d&rsquo;autres conditions m\u00e9dicales \u00e0 l&rsquo;avenir.<\/p>\n\n\n\n<p>EP Equity Investment, ind\u00e9pendante des participations industrielles du Groupe EP, se concentre sur l&rsquo;am\u00e9lioration de son portefeuille par le biais d&rsquo;investissements strat\u00e9giques dans des soci\u00e9t\u00e9s cot\u00e9es en bourse et des soci\u00e9t\u00e9s priv\u00e9es. L&rsquo;acquisition d&rsquo;une participation minoritaire dans Nanobacterie s&rsquo;inscrit dans sa strat\u00e9gie de soutien aux entreprises \u00e0 fort potentiel, leaders dans leurs domaines respectifs.<\/p>\n\n\n\n<p>En effet, AlphaOnco Swiss, la filiale de Nanobacterie bas\u00e9e au <a href=\"https:\/\/www.bioark.ch\/fr\/\">BioArk<\/a> de Monthey (canton du Valais), continue \u00e0 d\u00e9velopper ses solutions de pointe pour le traitement du cancer, en b\u00e9n\u00e9ficiant de la synergie de la recherche et du d\u00e9veloppement soutenus par leur soci\u00e9t\u00e9 m\u00e8re, Nanobacterie, qui a r\u00e9cemment obtenu <a href=\"https:\/\/ggba.swiss\/fr\/le-pionnier-de-la-nanomedecine-nanobacterie-se-distingue-par-ses-brevets\/\">une reconnaissance importante dans le classement des brevets de nanom\u00e9decine par Marks and Clerk<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>EP Equity Investment (EPEI), une soci\u00e9t\u00e9 qui investit dans des entreprises europ\u00e9ennes prometteuses, a acquis une participation de 24,99 % dans Nanobacterie afin de faire progresser le d\u00e9veloppement de traitements innovants pour le cancer de la prostate.<\/p>\n","protected":false},"author":6,"featured_media":24216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1140,1171,1168],"class_list":["post-24219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-oncology-fr-2","tag-pharma-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanobacterie obtient un investissement strat\u00e9gique d&#039;EP Equity<\/title>\n<meta name=\"description\" content=\"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobacterie obtient un investissement strat\u00e9gique d&#039;EP Equity\" \/>\n<meta property=\"og:description\" content=\"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-06T19:04:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-06T19:08:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nanobacterie obtient un investissement strat\u00e9gique d&rsquo;EP Equity\",\"datePublished\":\"2024-05-06T19:04:24+00:00\",\"dateModified\":\"2024-05-06T19:08:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\"},\"wordCount\":381,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\",\"name\":\"Nanobacterie obtient un investissement strat\u00e9gique d'EP Equity\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"datePublished\":\"2024-05-06T19:04:24+00:00\",\"dateModified\":\"2024-05-06T19:08:33+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Alors que Nanobacterie se pr\u00e9pare aux essais cliniques, l'investissement d'EPEI valide son approche innovante et renforce sa capacit\u00e9 \u00e0 relever les d\u00e9fis m\u00e9dicaux mondiaux.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobacterie obtient un investissement strat\u00e9gique d&#8217;EP Equity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobacterie obtient un investissement strat\u00e9gique d'EP Equity","description":"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/","og_locale":"fr_FR","og_type":"article","og_title":"Nanobacterie obtient un investissement strat\u00e9gique d'EP Equity","og_description":"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.","og_url":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-05-06T19:04:24+00:00","article_modified_time":"2024-05-06T19:08:33+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nanobacterie obtient un investissement strat\u00e9gique d&rsquo;EP Equity","datePublished":"2024-05-06T19:04:24+00:00","dateModified":"2024-05-06T19:08:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/"},"wordCount":381,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","keywords":["Biotech","Financing","Oncology","Pharma","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/","url":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/","name":"Nanobacterie obtient un investissement strat\u00e9gique d'EP Equity","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","datePublished":"2024-05-06T19:04:24+00:00","dateModified":"2024-05-06T19:08:33+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"EPEI a acquis une participation de 24,99 % dans Nanobacterie pour faire progresser traitements contre le cancer de la prostate.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","width":2360,"height":1622,"caption":"Alors que Nanobacterie se pr\u00e9pare aux essais cliniques, l'investissement d'EPEI valide son approche innovante et renforce sa capacit\u00e9 \u00e0 relever les d\u00e9fis m\u00e9dicaux mondiaux."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/nanobacterie-obtient-un-investissement-strategique-dep-equity-pour-faire-progresser-le-traitement-du-cancer-de-la-prostate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Nanobacterie obtient un investissement strat\u00e9gique d&#8217;EP Equity"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=24219"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24219\/revisions"}],"predecessor-version":[{"id":24223,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24219\/revisions\/24223"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/24216"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=24219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=24219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=24219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}